Cardiac Monitors in Maryland

Analytics for Life Inc. develops the CorVista® System, a cloud-based, AI-powered point-of-care diagnostic platform for non-invasive detection of cardiovascular diseases, including coronary artery disease (CAD) and pulmonary hypertension (PH). The proprietary system acquires cardiac and hemodynamic waveform signals at the point of care and transmits them securely to a cloud platform for real-time analysis using machine-learned diagnostic models derived from over 3,300 physiological features. The analytical engine was developed from prospective clinical studies on 10,000+ patients and is supported by over 80 issued patents and 81 pending across 40 invention families. The system provides results within minutes without specialized personnel, contrast agents, or stress testing, enabling physicians to diagnose and direct patient care efficiently while reducing diagnostic delays and loss-to-follow-up. Designed for integration into any professional healthcare setting with WiFi or cellular access, CorVista addresses multiple cardiovascular disease assessments in a single test. The company's regulatory strategy and quality framework are led by experienced personnel with expertise in US, EU, and international medical device submissions. The platform leverages distributed high-compute elastic cloud infrastructure with secure, HIPAA-compliant system design.

Terumo Medical Corporation (North America division of Terumo Corporation, founded 1921) is a global leader in medical devices and supplies, headquartered in Somerset, NJ, with manufacturing operations in Elkton, MD and Caguas, PR. The company operates in 160 countries with 2,000+ North American associates supporting 30,000+ global employees. Terumo Medical manufactures injection and infusion therapy devices, safety syringes (including the SurTract™ Safety Syringe with SafeR® passive safety technology), and related products for human and animal health markets. The Terumo Interventional Systems (TIS) division specializes in minimally invasive solutions for cardiology, peripheral arterial disease, embolotherapy, and interventional oncology, providing entry site management, lesion access, and therapeutic intervention devices. Terumo Health Outcomes (THO) delivers operational and clinical decision support to hospitals and clinicians. The Pharmaceutical Solutions Division (PSD) provides design and development services. Terumo performs integrated R&D, manufacturing, marketing, distribution, and sales. The company is recognized as one of the world's leading medical device manufacturers, serving diverse healthcare markets with a focus on quality, innovation, and patient outcomes.

Wearlinq manufactures the eWave, a FDA-cleared 6-lead wireless cardiac monitoring system designed for mobile cardiac telemetry and extended Holter monitoring. The device is imperceptible, featuring skin-like electrodes and a 5-day battery life per charge, with continuous data transmission to a cloud platform. The eWave captures six distinct ECG leads wirelessly, eliminating traditional wires while delivering diagnostic-grade cardiac data. The company operates Wearlinq Labs, an IDTF (Independent Diagnostic Testing Facility) with 33 years of cardiology service experience, staffed by Certified Cardiographic Technicians providing 24/7 coverage. Wearlinq delivers high-quality cardiology reports within 2 days and produces STAT reports daily. The platform includes a mobile application enabling real-time access to EKG data, digital diary functionality to correlate symptoms with cardiac events, connectivity monitoring to ensure signal quality, and 24/7 patient concierge support. The company targets cardiology practices, outpatient facilities, and hospitals requiring remote cardiac monitoring capabilities. Wearlinq received FDA clearance for the eWave and recently raised $14 million in funding, indicating active development and market expansion in the cardiac monitoring sector.

EpiWatch is an FDA-cleared, prescription-based mobile health platform that delivers real-time tonic-clonic seizure detection and alerting via Apple Watch and iPhone. The AI-powered application runs passively on wearable devices to monitor seizure activity and provides immediate alerts to caregivers when critical events occur, enabling rapid intervention and reducing the risk of Sudden Unexpected Nocturnal Death in Epilepsy (SUDEP). Designed for both pediatric and adult patients with epilepsy, EpiWatch integrates with family sharing and caregiver contact systems, requiring cellular or Wi-Fi connectivity for continuous monitoring. Available by prescription only in the United States at a monthly subscription fee, the platform empowers patients with independence while providing caregivers actionable intelligence during life-threatening events.